PepGen Announces Appointment of Two New Directors to its Board
PepGen (Nasdaq: PEPG), a clinical-stage biotechnology company focused on oligonucleotide therapies for neuromuscular diseases, has announced two strategic appointments to its Board of Directors. Lisa Wyman, current Chief Technical and Quality Officer at Scholar Rock, and Dr. Mitchell H. Finer, co-founder and Strategic Advisor for ElevateBio, join the board.
Wyman brings expertise in scaling manufacturing for clinical trials and regulatory navigation, having previously led technical operations at Generate:Biomedicines and Acceleron Pharma, where she contributed to the company's $11.5B acquisition by Merck. Dr. Finer brings 34+ years of genetic therapy experience, having led development of four approved therapies at bluebird bio and holding executive positions across multiple biotech companies.
These appointments aim to strengthen PepGen's board expertise as the company advances its mid-stage clinical trials and Enhanced Delivery Oligonucleotide platform development.
PepGen (Nasdaq: PEPG), una società biotecnologica in fase clinica focalizzata su terapie a base di oligonucleotidi per le malattie neuromuscolari, ha annunciato due nomine strategiche nel suo Consiglio di Amministrazione. Lisa Wyman, attuale Chief Technical and Quality Officer di Scholar Rock, e Dr. Mitchell H. Finer, co-fondatore e Consigliere Strategico di ElevateBio, si uniscono al consiglio.
Wyman porta con sé competenze nella scalabilità della produzione per studi clinici e nella navigazione normativa, avendo precedentemente guidato le operazioni tecniche presso Generate:Biomedicines e Acceleron Pharma, dove ha contribuito all'acquisizione dell'azienda da 11,5 miliardi di dollari da parte di Merck. Il Dr. Finer vanta oltre 34 anni di esperienza nella terapia genetica, avendo guidato lo sviluppo di quattro terapie approvate presso bluebird bio e ricoprendo posizioni dirigenziali in diverse aziende biotecnologiche.
Queste nomine mirano a rafforzare le competenze del consiglio di PepGen mentre l'azienda avanza nei suoi studi clinici di fase intermedia e nello sviluppo della piattaforma Enhanced Delivery Oligonucleotide.
PepGen (Nasdaq: PEPG), una empresa biotecnológica en etapa clínica centrada en terapias de oligonucleótidos para enfermedades neuromusculares, ha anunciado dos nombramientos estratégicos en su Junta Directiva. Lisa Wyman, actual Directora Técnica y de Calidad de Scholar Rock, y Dr. Mitchell H. Finer, cofundador y Asesor Estratégico de ElevateBio, se unen a la junta.
Wyman aporta experiencia en la escalabilidad de la producción para ensayos clínicos y en la navegación regulatoria, habiendo liderado anteriormente las operaciones técnicas en Generate:Biomedicines y Acceleron Pharma, donde contribuyó a la adquisición de la empresa por 11.5 mil millones de dólares por parte de Merck. El Dr. Finer tiene más de 34 años de experiencia en terapia genética, habiendo liderado el desarrollo de cuatro terapias aprobadas en bluebird bio y ocupando cargos ejecutivos en varias empresas biotecnológicas.
Estos nombramientos tienen como objetivo fortalecer la experiencia de la junta de PepGen a medida que la empresa avanza en sus ensayos clínicos en etapa intermedia y en el desarrollo de la plataforma de Oligonucleótidos de Entrega Mejorada.
PepGen (Nasdaq: PEPG)는 신경근 질환을 위한 올리고뉴클레오타이드 치료에 중점을 둔 임상 단계의 생명공학 회사로, 이사회에 두 명의 전략적 임명을 발표했습니다. Lisa Wyman은 현재 Scholar Rock의 최고 기술 및 품질 책임자이며, Dr. Mitchell H. Finer는 ElevateBio의 공동 창립자 및 전략 고문입니다.
Wyman은 Generate:Biomedicines와 Acceleron Pharma에서 기술 운영을 이끌었던 경험을 바탕으로 임상 시험을 위한 제조 규모 확대와 규제 탐색에 대한 전문성을 제공합니다. Dr. Finer는 bluebird bio에서 네 가지 승인된 치료법의 개발을 이끌었으며 여러 생명공학 회사에서 임원직을 역임한 34년 이상의 유전자 치료 경험을 가지고 있습니다.
이러한 임명은 PepGen의 이사회 전문성을 강화하여 회사가 중간 단계의 임상 시험 및 향상된 전달 올리고뉴클레오타이드 플랫폼 개발을 진행하는 데 도움을 주기 위한 것입니다.
PepGen (Nasdaq: PEPG), une entreprise de biotechnologie en phase clinique axée sur les thérapies par oligonucleotides pour les maladies neuromusculaires, a annoncé deux nominations stratégiques au sein de son Conseil d'Administration. Lisa Wyman, actuelle Directrice Technique et Qualité chez Scholar Rock, et Dr. Mitchell H. Finer, co-fondateur et Conseiller Stratégique chez ElevateBio, rejoignent le conseil.
Wyman apporte son expertise dans l'échelle de fabrication pour les essais cliniques et la navigation réglementaire, ayant précédemment dirigé les opérations techniques chez Generate:Biomedicines et Acceleron Pharma, où elle a contribué à l'acquisition de l'entreprise pour 11,5 milliards de dollars par Merck. Le Dr. Finer possède plus de 34 ans d'expérience dans la thérapie génique, ayant dirigé le développement de quatre thérapies approuvées chez bluebird bio et occupé des postes exécutifs dans plusieurs entreprises biopharmaceutiques.
Ces nominations visent à renforcer l'expertise du conseil de PepGen alors que l'entreprise avance dans ses essais cliniques de phase intermédiaire et le développement de sa plateforme d'Oligonucléotides à Livraison Améliorée.
PepGen (Nasdaq: PEPG), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Oligonukleotidtherapien für neuromuskuläre Erkrankungen konzentriert, hat zwei strategische Ernennungen in seinem Vorstand bekannt gegeben. Lisa Wyman, derzeit Chief Technical and Quality Officer bei Scholar Rock, und Dr. Mitchell H. Finer, Mitbegründer und Strategischer Berater von ElevateBio, treten dem Vorstand bei.
Wyman bringt Expertise in der Skalierung der Herstellung für klinische Studien und der regulatorischen Navigation mit, nachdem sie zuvor die technischen Abläufe bei Generate:Biomedicines und Acceleron Pharma geleitet hat, wo sie zur 11,5 Milliarden Dollar schweren Übernahme des Unternehmens durch Merck beigetragen hat. Dr. Finer bringt über 34 Jahre Erfahrung in der Gentherapie mit, nachdem er die Entwicklung von vier genehmigten Therapien bei bluebird bio geleitet und in mehreren Biotech-Unternehmen Führungspositionen innegehabt hat.
Diese Ernennungen zielen darauf ab, die Expertise des Vorstands von PepGen zu stärken, während das Unternehmen seine klinischen Studien in der mittleren Phase und die Entwicklung der Enhanced Delivery Oligonucleotide-Plattform vorantreibt.
- Strategic board appointments bring extensive expertise in manufacturing scale-up and clinical development
- New directors have successful track record in drug approvals and company acquisitions
- Enhanced leadership expertise for advancing mid-stage clinical trials
- None.
“We are thrilled to welcome Lisa and Mitch to our Board of Directors,” said James McArthur, PhD, President and CEO of PepGen. “Lisa’s proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies through global regulatory agencies, combined with Mitch’s extensive experience in driving scientific innovation and translating breakthrough research into life-changing therapies, will broaden and strengthen our Board of Directors at this crucial time for PepGen. Their guidance will be invaluable as we advance our mid-stage clinical trials and continue to unlock the full potential of our cutting-edge Enhanced Delivery Oligonucleotide platform, with the ultimate goal of bringing transformative therapeutics to patients with severe neuromuscular conditions.”
Ms. Wyman was recently appointed Chief Technical and Quality Officer at Scholar Rock. Previously, she served as Chief Technical Operations Officer and Chief Digital Officer at Generate:Biomedicines, where she led teams across CMC, technical development, IT, quality, and supply operations. Prior to that, Ms. Wyman was Senior Vice President of Technical Operations and Quality at Acceleron Pharma Inc., playing a pivotal role in transforming the company from a research-focused entity to a commercial-stage biotech firm, culminating in its
Dr. Finer is a co-founder and Strategic Advisor for ElevateBio, where he previously served as President of Research and Development and as Chief Executive Officer of Life Edit Therapeutics, its gene editing business. Before ElevateBio, he served as Chief Scientific Officer at bluebird bio, where he led the development of four approved therapies: Abecma® for multiple myeloma, Zynteglo® for beta thalassemia, Lyfgenia™ for sickle cell anemia, and Skysona® for childhood cerebral adrenoleukodystrophy. With over 34 years of experience in genetic therapies, he has co-founded, held executive roles in, or served on the boards of multiple companies, including Adverum Biotechnologies, Cell Genesys, CODA Biotherapeutics, the Gencell division of Aventis Pharma (now Sanofi), Genteric, Intracel, Novacell (now Viacyte, acquired by Vertex), Oncorus, Semma Therapeutics, TCR Therapeutics, and Turmeric Acquisition Holdings. Dr. Finer is an inventor on over 15 issued
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
For more information, please visit PepGen.com. Follow PepGen on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331028573/en/
Investor Contact
Dave Borah, CFA
SVP, Investor Relations and Corporate Communications
dborah@pepgen.com
Media Contact
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
Source: PepGen Inc.
FAQ
Who are the new board members appointed to PepGen (PEPG)?
What experience does Lisa Wyman bring to PepGen's (PEPG) board?
What is Dr. Mitchell Finer's background and contribution to PepGen (PEPG)?
How do these board appointments align with PepGen's (PEPG) current business strategy?
